858 Therapeutics
Latest round
- Series B
Last raised
- Jun 2024
Total raised
- $85M
Investors
- 8
About 858 Therapeutics
Based in California, US, and founded in 2019, 858 Therapeutics, Inc. operates as a biotechnology company that develops small molecules directed against therapeutic targets in oncology, including proteins that control Ribonucleic acid and the immune response. In September 2024, 858 Therapeutics, Inc. 858 Therapeutics built a platform that focuses on Ribonucleic acid (RNA) metabolism and immune sensing mechanisms to discover small-molecule therapeutics for the treatment of cancer. The platform includes a suite of proprietary in vitro biochemical and biophysical assays, as well as cellular assays. 858 Therapeutics plans to enter the clinic with its lead products that have the potential to treat cancers that are resistant to current therapies and expand its team to about 40 people within the next 18 months. It also plans to bring leading academic scientists with specialization in the field to contribute to the company.
Who invested in 858 Therapeutics
8 investors across 2 rounds
See all investors in 858 Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about 858 Therapeutics
Who invested in 858 Therapeutics?
858 Therapeutics has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has 858 Therapeutics raised?
858 Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did 858 Therapeutics last raise money?
858 Therapeutics's most recent round on record is a Series B, in Jun 2024.
What does 858 Therapeutics do?
Based in California, US, and founded in 2019, 858 Therapeutics, Inc.
Where is 858 Therapeutics headquartered?
858 Therapeutics is headquartered in San Diego, US.
Which VCs invest in companies like 858 Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at 858 Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like 858 Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.